Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03857477

The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.

Sponsor: Institute of Cancer Research, United Kingdom

View on ClinicalTrials.gov

Summary

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. A pilot of 300 men were recruited aiming to inform the feasibility and accessibility of the study approach. The full study is an extension of the pilot study aiming to recruit a total of 5000 men.

Official title: The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.

Key Details

Gender

MALE

Age Range

55 Years - 69 Years

Study Type

OBSERVATIONAL

Enrollment

4700

Start Date

2019-03-14

Completion Date

2028-12-31

Last Updated

2025-04-29

Healthy Volunteers

Yes

Conditions

Interventions

GENETIC

Genetic SNP profiling

Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

OTHER

Prostate cancer screening

Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.

PROCEDURE

MRI Scan

MRI scan will be offered to men identified within the top 10% genetic risk score profile.

PROCEDURE

Prostate biopsy

Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.

Locations (1)

Institute of Cancer Research and Royal Marsden Hospital

Sutton, Surrey, United Kingdom